Appointment of Stifel as Joint Broker

11 January 2022

Instem Life Science Systems plc
("Instem", the "Group" or the "Company")

Appointment of Stifel as Joint Broker

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces the appointment of Stifel Nicolaus Europe Limited (“Stifel”) as the Company’s joint broker with immediate effect.

Stifel will work alongside Instem’s existing broker, Singer Capital Markets, as the Company focuses on further increasing liquidity and engagement with US-based institutional investors.

For further information, please contact:

Instem plc Via Walbrook
Phil Reason, CEO  
Nigel Goldsmith, CFO  
Singer Capital Markets (Nominated Adviser & Broker) +44 (0) 20 7496 3000
Peter Steel  
Alex Bond  
Rachel Hayes  
Stifel Nicolaus Europe Limited (Joint Broker) +44 (0)20 7710 7600
Ben Maddison  
Alex Price  
Wallbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome  
Nicholas Johnson  

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.

To learn more about Instem solutions and its mission, please visit instem.com.